CDMO Market Insight, Pricing and Benchmarking Reports

NICE INSIGHT REPORT

Cell & Gene Therapy:2023 Market Analysis, CDMO Pricing and Competitor Benchmarking

Published August, 2023

230 pages of Cell & Gene Therapy market analysis
2023 pricing comparison for broad CDMO services
Market intelligence for viral vector and plasmid DNA manufacture
94 unique Cell & Gene Therapy CDMO profiles
Benchmarking of top CDMOs’ proprietary technologies
Scientific insights from PhDs, CDMO owners and researchers

Key market insights for innovators, CDMOs and investors in the Cell & Gene Therapy industry.

Scientific analysis on ATMPs — The New Frontier

Stay up to date with market trends for Cell and Gene Therapies straight from the industry’s KOLs. Our Market Analysis gains insights from CDMO owners, PhDs and researchers across advanced therapeutics. Measure your business against your peers using our robust analysis of AAV, lentiviral and plasmid DNA manufacture.

Exclusive CDMO pricing data for benchmarking

Our pricing matrix uses data from across the industry so you can make informed decisions for your business. Compare your prices over time against your peers in respect to material costs, infrastructure and development process.

Published August, 2023

Unequaled price benchmarking and market intelligence for Cell & Gene Therapy manufacturing — all in one report.

Request A Sample

The Cell & Gene Therapy: 2023 Market Analysis, CDMO Pricing and Benchmarking provides

Current pricing data for manufacturing across advanced Cell & Gene Therapies

94 significant CDMO profiles including capabilities, capacity, proprietary technologies and locations

Scientific analysis of the manufacturing process for AAV, lentivirus and plasmid DNA

Unique supply chain challenges and the shift from supply chain to value chain management

Investment outlook into new modalities — analyzing economic temperature and regulatory conditions

Innovations and breakthroughs that are invaluable to the next generation of therapies

Request A Sample

Over 1000 hours of data collection and analysis

from interviews, primary research and progressive study

Executive Summary

Section I:
View from the Top: Cell and Gene Therapy Successes and Promise
−+

Section II:
Understanding a Rapidly Evolving Sector
−+

Section III:
The Cell and Gene Therapy and Outsourced Service Markets
−+

Section IV:
Update on Regulatory Guidance for Cell and Gene Therapies
−+

Section V:
Recent Cell and Gene Therapy Clinical Trials Struggles
−+

Section VI:
The Next Frontier – Non-Viral Delivery and Gene Editing

Section VII:
AAV Manufacture for Gene Therapy
−+

Section VIII:
Lentivirus Manufacture for CAR T-Cell Therapy
−+

Section IX:
CDMO Pricing for Viral Vector Manufacture
−+

Section X:
Plasmid DNA Manufacture
−+

Section XI:
CDMO Pricing for Plasmid DNA Manufacture
−+

Section XII:
Cell and Gene CDMO Company Overview and Profiles

Appendix I:
References

Request A Sample

NICE INSIGHT REPORT

Cell & Gene Therapy:2023 Market Analysis, CDMO Pricing and Competitor Benchmarking

Key market insights for innovators, CDMOs and investors in the Cell & Gene Therapy industry.

Scientific analysis on ATMPs — The New Frontier

Exclusive CDMO pricing data for benchmarking

Published August, 2023

The Cell & Gene Therapy: 2023 Market Analysis, CDMO Pricing and Benchmarking provides

Over 1000 hours of data collection and analysis

from interviews, primary research and progressive study

Table of Contents

Executive Summary

Executive Summary

Section I:View from the Top: Cell and Gene Therapy Successes and Promise−+

Section I:

View from the Top: Cell and Gene Therapy Successes and Promise

Section II:Understanding a Rapidly Evolving Sector−+

Section II:

Understanding a Rapidly Evolving Sector

Section III:The Cell and Gene Therapy and Outsourced Service Markets−+

Section III:

The Cell and Gene Therapy and Outsourced Service Markets

Section IV:Update on Regulatory Guidance for Cell and Gene Therapies−+

Section IV:

Update on Regulatory Guidance for Cell and Gene Therapies

Section V:Recent Cell and Gene Therapy Clinical Trials Struggles−+

Section V:

Recent Cell and Gene Therapy Clinical Trials Struggles

Section VI:The Next Frontier – Non-Viral Delivery and Gene Editing

Section VI:

The Next Frontier – Non-Viral Delivery and Gene Editing

Section VII:AAV Manufacture for Gene Therapy−+

Section VII:

AAV Manufacture for Gene Therapy

Section VIII:Lentivirus Manufacture for CAR T-Cell Therapy−+

Section VIII:

Lentivirus Manufacture for CAR T-Cell Therapy

Section IX:CDMO Pricing for Viral Vector Manufacture−+

Section IX:

CDMO Pricing for Viral Vector Manufacture

Section X:Plasmid DNA Manufacture−+

Section X:

Plasmid DNA Manufacture

Section XI:CDMO Pricing for Plasmid DNA Manufacture−+

Section XI:

CDMO Pricing for Plasmid DNA Manufacture

Section XII:Cell and Gene CDMO Company Overview and Profiles

Section XII:

Cell and Gene CDMO Company Overview and Profiles

Appendix I:References

Appendix I:

References

Section I:
View from the Top: Cell and Gene Therapy Successes and Promise
−+

Section II:
Understanding a Rapidly Evolving Sector
−+

Section III:
The Cell and Gene Therapy and Outsourced Service Markets
−+

Section IV:
Update on Regulatory Guidance for Cell and Gene Therapies
−+

Section V:
Recent Cell and Gene Therapy Clinical Trials Struggles
−+

Section VI:
The Next Frontier – Non-Viral Delivery and Gene Editing

Section VII:
AAV Manufacture for Gene Therapy
−+

Section VIII:
Lentivirus Manufacture for CAR T-Cell Therapy
−+

Section IX:
CDMO Pricing for Viral Vector Manufacture
−+

Section X:
Plasmid DNA Manufacture
−+

Section XI:
CDMO Pricing for Plasmid DNA Manufacture
−+

Section XII:
Cell and Gene CDMO Company Overview and Profiles

Appendix I:
References